EN DE
Watch Q32 Bio Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Q32 Bio Inc (QTTB) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Q32 Bio Inc stock $7.81, price $9.25, that is 15.6% below the price, quality 70 out of 100. Rating: overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

QB Q32 Bio Inc logo Some data Nov 7, 2026

Q32 Bio Inc

QTTB · US
Solid, but expensive

Our calculation puts a fair price 16% below what the stock costs today.

Quality 70/100
Highly profitable · 60.0% net margin (TTM)
Low debt
Ranks above peers (10/12)
Costs just 2.6 times its yearly profit.
Mixed Growth (revenue 5y +81.9 %/yr in USD)
Wide moat 89/100 · thin data
Insiders bought $30.0M (6M) · sold $320,396
Some data
Fair value $7.81 · Overvalued
Negative free cash flow
⚠ Dilution
Watch Q32 Bio Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$156.78 $1.36 Fair Value $7.81 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $1.36 – $156.78 · fair‑value band $6.09 – $9.53 · the $9.25 price screens above the $7.81 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Q32 Bio in your weekly email

Every Wednesday you see whether Q32 Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.

Show moreShow less

The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.

It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Stock analysis

Q32 Bio Inc (QTTB) currently trades at $9.25, while our model-based Fair Value estimate is $7.81, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $16.56 per share, and 4 of the 13 models we run sit above the $9.25 price.

Bear case: the Asset-Based group reads lowest at $1.18, and 9 of the 13 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $6.09 (bear) to $9.53 (bull), the price of $9.25 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Q32 Bio Inc reported revenue of $53.7M in FY2025 versus $34.0M in FY2021, a compound +12.1%/yr. Reported net income was $29.8M in FY2025.

Key figures

Market cap $277M Micro · P/E ratio 2.6 · P/S ratio 1.43 · EPS (TTM) $3.60 · Net margin 55.5% · Return on equity 24.0% · Return on assets (EBIT) −41.8% (5-year average) · Operating margin 34.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 89 out of 100 (low confidence).

What moves the price

The share trades about 57% below its 52-week high and 379% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −16%, QTTB screens richer than that median.

Fair Value models

Bear $6.09 Fair Value $7.81 Bull $9.53
Price $9.25 · Downside -15.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($3.09 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $7.95 $9.58 $12.21 76
EPV $5.07 $5.49 $5.83 74
ROIC Compounder $5.07 $5.49 $5.83 70
All 13 models by family
DCF Models
Owner Earnings $7.95 $9.58 $12.21 76
Earnings-Based
Graham-Dodd $6.78 $8.28 $9.32 65
EPV $5.07 $5.49 $5.83 74
Multiples
P/E Multiple $16.44 $21.92 $27.41 63
P/S Multiple $4.71 $6.29 $7.86 58
P/B Multiple $4.74 $6.32 $7.90 55
EV/EBIT $8.30 $10.70 $13.10 66
EV/EBITDA $7.17 $9.19 $11.21 67
EV/Revenue $4.87 $6.49 $8.10 54
Asset-Based
NCAV (Graham) $0.7800 $1.18 $1.47 55
Economic Profit
Residual Income $3.27 $3.76 $5.34 68
ROIC Compounder $5.07 $5.49 $5.83 70
Growth Earnings
Growth-Adj P/E $11.59 $16.56 $21.53 65

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 70/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 93
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 67
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 69
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $30.0M, most recently on May 28, 2026. Over the same period, 3 people sold shares worth $320,396. Buying cluster

  • SaleLee KalowskiCFO and President4× since Dec 2, 2025: 18,340 shares, avg. $6.87$126,007Oct 6, 2026
  • SaleShelia M. VioletteChief Scientific Officer3× since Feb 25, 2026: 6,530 shares, avg. $10.21$66,660Oct 6, 2026
  • SaleJodie Pope MorrisonCEO, Director4× since Dec 2, 2025: 45,468 shares, avg. $6.87$312,333Oct 6, 2026
  • BuyOrbiMed Capital GP VII LLCDirector, 10% owner1,875,000 shares at $8.00$15.0MMay 28, 2026
  • BuyDiyong XuDirector, 10% owner1,875,000 shares at $8.00$15.0MMay 28, 2026

Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 57/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+100.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+81.9%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4,821.0% (2020) → 31.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

QTTB screens overvalued: fair value 16% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Q32 Bio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 10/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 70 · Top 25%
Fair Value upside −15.6% · Above median
Profitability
Return on equity (12 months) 24.0% · Top 25%
Return on assets 48.3% · Top 25%
Net margin (12 months) 60.0% · Top 25%
Operating margin (12 months) 34.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.08× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 2.6× · Cheapest 25%
P/B 6.59× · Priciest 25%
P/S (12 months) 5.15× · Cheaper than median
EV/EBITDA 12.4× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)13 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)96 · sector 0
HEALTH (low debt)96 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs QTTB
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs QTTB
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs QTTB
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs QTTB
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs QTTB
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs QTTB
argenx SE ARGX $927.21 $908.40 −2% vs QTTB
CSL Limited CSL A$200.77 A$183.04 −9% vs QTTB
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs QTTB
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs QTTB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Q32 Bio Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Q32 Bio Inc Fair Value". https://www.fairvalue-calculator.com/stock/QTTB

Frequently asked questions

Is Q32 Bio Inc (QTTB) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $7.81 versus a price of $9.25, about 16% lower (overvalued).
What is the fair value of QTTB?
Our model-based fair value for Q32 Bio Inc is $7.81 (as of Nov 7, 2026), built from audited fundamentals. The current price: $9.25.
What is the quality score of QTTB?
Q32 Bio Inc has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Q32 Bio Inc (QTTB)?
Our model-based price target is the fair value of $7.81 (as of Nov 7, 2026) from 13 valuation models. Cautious scenario $6.09, optimistic scenario $9.53. It is a calculation from audited fundamentals, not an analyst target.
What is the Q32 Bio Inc stock forecast for 2026?
Our models put fair value at $7.81, about 16% lower versus a price of $9.25 (overvalued). Cautious scenario $6.09, optimistic scenario $9.53. The calculation is refreshed regularly with new filings.
What is the revenue of Q32 Bio Inc (QTTB)?
Q32 Bio Inc reported trailing-twelve-month revenue of about $53.7M (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Q32 Bio Inc (QTTB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Q32 Bio Inc it is $7.81 per share (as of Nov 7, 2026), against a price of $9.25. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Q32 Bio Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, QTTB trades above its calculated fair value: price $9.25, fair value $7.81, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of QTTB?
No. The price is what the market pays today ($9.25); the fair value is what the company's own numbers justify ($7.81). For Q32 Bio Inc the two are $1.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Q32 Bio Inc worth?
The market values Q32 Bio Inc at about $277M (market capitalisation, as of Nov 7, 2026). Per share that is $9.25; our models calculate a fair value of $7.81 per share.
What do the bullish and bearish scenarios say about QTTB?
Our models span a range for Q32 Bio Inc: cautious scenario $6.09, base $7.81, optimistic $9.53 per share (as of Nov 7, 2026, price $9.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of QTTB?
Q32 Bio Inc trades at a price-to-earnings ratio of 2.6 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.81 is built from several models across several years. Other multiples: P/B 6.6, P/S 5.2, EV/EBITDA 12.4.
How solid is the balance sheet of Q32 Bio Inc (QTTB)?
Balance-sheet figures for Q32 Bio Inc (as of Nov 7, 2026): return on equity 24.0%, debt of 0.08 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is QTTB from its 52-week high?
Q32 Bio Inc trades at $9.25, about 57% below its 52-week high of $21.38 and 379% above the low of $1.93 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $7.81 is for.
Which stocks are comparable to Q32 Bio Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Q32 Bio Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $9.25, calculated fair value $7.81 (−16%), Quality Score 70/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of QTTB calculated?
We run Q32 Bio Inc through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $7.81 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Q32 Bio Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Q32 Bio Inc (QTTB)?
The closing price on Nov 6, 2026 was $9.25. Our model-based fair value is $7.81, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Q32 Bio Inc right now?
Solid but not exceptional quality (70/100) and above fair value, neither a clear bargain nor a standout compounder. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Q32 Bio Inc

How large is the market capitalisation of Q32 Bio Inc (QTTB)?
The market capitalisation of Q32 Bio Inc is $277M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Q32 Bio Inc (QTTB)?
The price-to-sales ratio of Q32 Bio Inc is 1.43 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Q32 Bio Inc (QTTB)?
Earnings per share at Q32 Bio Inc are $3.60 (price ÷ EPS = P/E 2.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Q32 Bio Inc (QTTB)?
The net margin of Q32 Bio Inc is 55.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Q32 Bio Inc (QTTB)?
The return on equity (ROE) of Q32 Bio Inc is 24.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Q32 Bio Inc (QTTB)?
On an EBIT basis the return on assets of Q32 Bio Inc is −41.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Q32 Bio Inc (QTTB)?
The operating margin of Q32 Bio Inc is 34.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Q32 Bio Inc (QTTB) generate?
The free cash flow of Q32 Bio Inc is −$33.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Q32 Bio Inc (QTTB) hold?
Q32 Bio Inc holds more cash than debt, $33.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Q32 Bio Inc in the live analysis

One click puts Q32 Bio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.